Aspen Neuroscience (ASPE) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
9 Oct, 2026Company overview and business model
Clinical-stage regenerative medicine developer focused on autologous iPSC-derived therapies for CNS diseases; lead candidate sasineprocel is a single-dose cell therapy intended to replace lost dopamine neurons in Parkinson’s disease (PD).
Platform combines patient-cell reprogramming, differentiation, AI/ML and genomic analysis, automated manufacturing, and quality-control assays; worldwide commercial rights across programs.
Sasineprocel uses a patient’s own cells and is designed to avoid post-treatment immunosuppression; manufacturing begins with a minimally invasive skin biopsy and proceeds through fibroblast, iPSC and dopaminergic precursor stages.
Pipeline includes sasineprocel for sporadic and genetic PD and an autologous, gene-edited microglia program initially targeting pediatric leukodystrophies.
Financial performance and metrics
Net loss was $62.1M in FY2025 vs $48.6M in FY2024; H1 2026 net loss was $36.5M vs $31.8M in H1 2025.
R&D expense was $41.8M in FY2025 vs $35.6M in FY2024; H1 2026 R&D was $28.5M vs $20.8M in H1 2025, driven mainly by sasineprocel development and production.
Cash, cash equivalents and marketable securities totaled $72.4M at June 30, 2026, down from $110.7M at Dec. 31, 2025; accumulated deficit was $264.9M.
H1 2026 operating cash use was $34.5M vs $30.6M in H1 2025; management concluded substantial doubt existed about continuing as a going concern without financing.
Operations have generated no product revenue; approximately $340M of gross preferred-stock proceeds funded operations through June 2026, including $115.6M from the 2025 Series C financing.
Use of proceeds and capital allocation
Net proceeds, together with existing cash and marketable securities, are intended to fund the Phase 1/2a ASPIRO trial and initiate a Phase 3 sasineprocel trial in sporadic and genetic PD.
Additional planned uses include microglia-program R&D, including IND-enabling studies, plus working capital and general corporate purposes; some funds may support future complementary licenses, acquisitions or investments.
Proceeds plus existing liquidity are expected to support operations for a period based on current plans, but are not expected to fund completion of ASPIRO, Phase 3 or candidate development; additional capital will be required.
